EX-10.1
from 8-K
2 pages
April 18, 2017 Oragenics, Inc. Attention: Alan Joslyn, CEO Dear Dr. Joslyn: We Are Pleased to Advise You That Intrexon Corporation (“Intrexon”) Hereby Commits to Provide Oragenics, Inc. (The “Borrower”) With an Unsecured Loan (The “Loan”) Subject to the Following Terms and Conditions: 1. Loan Terms. (A) Purpose: The Proceeds of the Loan Will Be Used to Fund Borrower’s Ag013 Research and Clinical Trials. (B) Loan Amount: $2,400,000 Which May Be Made in One or More Tranches at the Election of the Borrower. (C) Interest: The Interest Rate Charged on the Outstanding Principal Balance of the Loan Shall Equal 12% Per Annum. All Accrued and Unpaid Principal and Interest Under the Loan Shall Be Due and Payable Upon the Maturity Date of the Loan. (D) Maturity Date: Two (2) Years From the Date of the Closing (As Defined Below). (E) Prepayment: Borrower May Prepay the Loan in Whole or in Part (Along With Any Accrued Interest), Without Penalty or Premium, at Any Time Prior to the Maturity Date. 2. Security. the Loan Will Be Unsecured and Non-Convertible. 3. Costs and Expenses. Each Party Shall Pay All Costs and Expenses Incurred by Such Party in Connection With the Loan. 4. Conditions to Closing. the Closing of the Loan Is Conditioned Upon: (A) Execution of a Note Purchase Agreement and Unsecured Promissory Note (The “Loan Documents”) in Form Acceptable to the Parties
12/34/56
EX-10.2
from 8-K
2 pages
First Amendment to Revolving Credit Agreement Between: The Koski Family Limited Partnership, a Texas Limited Partnership as “Lender” and Oragenics, Inc., a Florida Corporation as “Borrower”. Additional Loan Amount: $500,000.00 Date: January 24, 2011 First Amendment to Revolving Credit Agreement
12/34/56
